Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.01 or -0.91% from the prior close of $1.1. The stock opened at $1.1 and touched a low of ...
Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...
Auburn doubled up visiting Stanford Olympia 52-26 to notch its first Sangamo Conference win Monday at Doglio Gymnasium. The AHS girls also split a pair of non-conference games, falling 56-37 to ...
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...
On Thursday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $1.1 which represents no change from the prior close of of $1.1. The stock opened at $1.12 and touched a low ...
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...
Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...